ReviewCNS neuroscience & therapeutics2025
Targeting Excitatory Glutamate Receptors for Morphine Tolerance: A Narrative Review.
Review in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Role of Muscarinic Receptor Signaling Processes in Specific Aspects of Morphine-Induced Respiratory Depression in Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Pathological Roles of Astrocytes in Traumatic Brain Injury.CNS neuroscience & therapeutics · 2026Review
- Decoding chronic pain: integrating genetics, neuroimaging, and AI for precision management.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOpioids remain a primary treatment for moderate-to-severe chronic pain, but prolonged use frequently induces analgesic tolerance. Excitatory glutamate receptors, ubiquitous in the central and peripheral nervous systems, are pivotal in physiological and pathological processes and are now recognized as significant contributors to opioid tolerance development.
methodsWe comprehensively analyzed experimental data from our team's intensive investigations over the past 10 years, alongside relevant peer-reviewed studies on glutamate receptor mechanisms in opioid tolerance.
resultsExcitatory glutamate receptors (including NMDA, AMPA, and metabotropic subtypes) fundamentally regulate neuroadaptations underlying morphine tolerance. Our work and others' demonstrate their involvement in synaptic plasticity, neuroinflammation, and downstream signaling pathways that drive tolerance.
conclusionsTargeting excitatory glutamate receptors presents a promising therapeutic strategy for mitigating opioid tolerance. Future research should prioritize elucidating receptor-specific mechanisms, peripheral-central nervous system crosstalk, and translating preclinical findings into clinically viable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.